APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sulfonylurea Hypoglycemic Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Sulfonylurea Hypoglycemic Drugs Market Outlook and Growth Opportunities 2026

23 December 2025199 pages

Choose your research edition.

Industry ResearchSulfonylurea Hypoglycemic Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Sulfonylurea Hypoglycemic Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Sulfonylurea Hypoglycemic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sulfonylurea Hypoglycemic Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Sulfonylurea Hypoglycemic Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Sulfonylurea Hypoglycemic Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Sulfonylurea Hypoglycemic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Sulfonylurea Hypoglycemic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Sulfonylurea Hypoglycemic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Sulfonylurea Hypoglycemic Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Sulfonylurea Hypoglycemic Drugs market include United Laboratories, Takeda, Sanofi, Novo Nordisk, Merck, Eli Lilly, Jiangsu Hengrui Pharmaceuticals, Pfizer and Beijing Double-Crane Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Sulfonylurea Hypoglycemic Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sulfonylurea Hypoglycemic Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sulfonylurea Hypoglycemic Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Sulfonylurea Hypoglycemic Drugs market.

Sulfonylurea Hypoglycemic Drugs Segment by Company

United Laboratories

Takeda

Sanofi

Novo Nordisk

Merck

Eli Lilly

Jiangsu Hengrui Pharmaceuticals

Pfizer

Beijing Double-Crane Pharmaceutical

Huadong Medicine

GSK

Beijing Beilu Pharmaceutical

AstraZeneca

Boehringer Ingelheim

Sulfonylurea Hypoglycemic Drugs Segment by Type

First Generation Sulfonylureas

Second Generation Sulfonylureas

Third Generation Sulfonylureas

Sulfonylurea Hypoglycemic Drugs Segment by Application

Pharmacy

Hospital

Clinic

Others

Sulfonylurea Hypoglycemic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Sulfonylurea Hypoglycemic Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Sulfonylurea Hypoglycemic Drugs key companies, revenue, market share, and recent developments.

3. To split the Sulfonylurea Hypoglycemic Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Sulfonylurea Hypoglycemic Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Sulfonylurea Hypoglycemic Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Sulfonylurea Hypoglycemic Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sulfonylurea Hypoglycemic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sulfonylurea Hypoglycemic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sulfonylurea Hypoglycemic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sulfonylurea Hypoglycemic Drugs industry.

Chapter 3: Detailed analysis of Sulfonylurea Hypoglycemic Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Sulfonylurea Hypoglycemic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Sulfonylurea Hypoglycemic Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Sulfonylurea Hypoglycemic Drugs Industry Trends Table 2. Sulfonylurea Hypoglycemic Drugs Industry Drivers Table 3. Sulfonylurea Hypoglycemic Drugs Industry Opportunities and Challenges Table 4. Sulfonylurea Hypoglycemic Drugs Industry Restraints Table 5. Global Sulfonylurea Hypoglycemic Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Sulfonylurea Hypoglycemic Drugs Revenue Share by Company (2021-2026) Table 7. Global Sulfonylurea Hypoglycemic Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Sulfonylurea Hypoglycemic Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Sulfonylurea Hypoglycemic Drugs Company, Product Type & Application Table 10. Global Sulfonylurea Hypoglycemic Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Sulfonylurea Hypoglycemic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of First Generation Sulfonylureas Table 15. Significant Companies of Second Generation Sulfonylureas Table 16. Significant Companies of Third Generation Sulfonylureas Table 17. Global Sulfonylurea Hypoglycemic Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Sulfonylurea Hypoglycemic Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Sulfonylurea Hypoglycemic Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type (2021-2026) Table 21. Global Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Pharmacy Table 23. Significant Companies of Hospital Table 24. Significant Companies of Clinic Table 25. Significant Companies of Others Table 26. Global Sulfonylurea Hypoglycemic Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Sulfonylurea Hypoglycemic Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Sulfonylurea Hypoglycemic Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application (2021-2026) Table 30. Global Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application (2027-2032) Table 31. Global Sulfonylurea Hypoglycemic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Sulfonylurea Hypoglycemic Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Sulfonylurea Hypoglycemic Drugs Sales Value Share by Region (2021-2026) Table 34. Global Sulfonylurea Hypoglycemic Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Sulfonylurea Hypoglycemic Drugs Sales Value Share by Region (2027-2032) Table 36. Global Sulfonylurea Hypoglycemic Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Sulfonylurea Hypoglycemic Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Sulfonylurea Hypoglycemic Drugs Sales Value Market Share by Country (2021-2026) Table 39. Global Sulfonylurea Hypoglycemic Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Sulfonylurea Hypoglycemic Drugs Sales Value Market Share by Country (2027-2032) Table 41. United Laboratories Company Information Table 42. United Laboratories Business Overview Table 43. United Laboratories Sulfonylurea Hypoglycemic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. United Laboratories Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 45. United Laboratories Recent Development Table 46. Takeda Company Information Table 47. Takeda Business Overview Table 48. Takeda Sulfonylurea Hypoglycemic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Takeda Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 50. Takeda Recent Development Table 51. Sanofi Company Information Table 52. Sanofi Business Overview Table 53. Sanofi Sulfonylurea Hypoglycemic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Sanofi Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 55. Sanofi Recent Development Table 56. Novo Nordisk Company Information Table 57. Novo Nordisk Business Overview Table 58. Novo Nordisk Sulfonylurea Hypoglycemic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Novo Nordisk Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 60. Novo Nordisk Recent Development Table 61. Merck Company Information Table 62. Merck Business Overview Table 63. Merck Sulfonylurea Hypoglycemic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Merck Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 65. Merck Recent Development Table 66. Eli Lilly Company Information Table 67. Eli Lilly Business Overview Table 68. Eli Lilly Sulfonylurea Hypoglycemic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Eli Lilly Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 70. Eli Lilly Recent Development Table 71. Jiangsu Hengrui Pharmaceuticals Company Information Table 72. Jiangsu Hengrui Pharmaceuticals Business Overview Table 73. Jiangsu Hengrui Pharmaceuticals Sulfonylurea Hypoglycemic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Jiangsu Hengrui Pharmaceuticals Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 75. Jiangsu Hengrui Pharmaceuticals Recent Development Table 76. Pfizer Company Information Table 77. Pfizer Business Overview Table 78. Pfizer Sulfonylurea Hypoglycemic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Pfizer Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 80. Pfizer Recent Development Table 81. Beijing Double-Crane Pharmaceutical Company Information Table 82. Beijing Double-Crane Pharmaceutical Business Overview Table 83. Beijing Double-Crane Pharmaceutical Sulfonylurea Hypoglycemic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Beijing Double-Crane Pharmaceutical Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 85. Beijing Double-Crane Pharmaceutical Recent Development Table 86. Huadong Medicine Company Information Table 87. Huadong Medicine Business Overview Table 88. Huadong Medicine Sulfonylurea Hypoglycemic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Huadong Medicine Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 90. Huadong Medicine Recent Development Table 91. GSK Company Information Table 92. GSK Business Overview Table 93. GSK Sulfonylurea Hypoglycemic Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. GSK Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 95. GSK Recent Development Table 96. Beijing Beilu Pharmaceutical Company Information Table 97. Beijing Beilu Pharmaceutical Business Overview Table 98. Beijing Beilu Pharmaceutical Sulfonylurea Hypoglycemic Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Beijing Beilu Pharmaceutical Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 100. Beijing Beilu Pharmaceutical Recent Development Table 101. AstraZeneca Company Information Table 102. AstraZeneca Business Overview Table 103. AstraZeneca Sulfonylurea Hypoglycemic Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. AstraZeneca Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 105. AstraZeneca Recent Development Table 106. Boehringer Ingelheim Company Information Table 107. Boehringer Ingelheim Business Overview Table 108. Boehringer Ingelheim Sulfonylurea Hypoglycemic Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Boehringer Ingelheim Sulfonylurea Hypoglycemic Drugs Product Portfolio Table 110. Boehringer Ingelheim Recent Development Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Sulfonylurea Hypoglycemic Drugs Product Image Figure 2. Global Sulfonylurea Hypoglycemic Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sulfonylurea Hypoglycemic Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Sulfonylurea Hypoglycemic Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. First Generation Sulfonylureas Image Figure 8. Second Generation Sulfonylureas Image Figure 9. Third Generation Sulfonylureas Image Figure 10. Global Sulfonylurea Hypoglycemic Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Sulfonylurea Hypoglycemic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type (2021-2032) Figure 13. Pharmacy Image Figure 14. Hospital Image Figure 15. Clinic Image Figure 16. Others Image Figure 17. Global Sulfonylurea Hypoglycemic Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Sulfonylurea Hypoglycemic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application (2021-2032) Figure 20. Global Sulfonylurea Hypoglycemic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Sulfonylurea Hypoglycemic Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Sulfonylurea Hypoglycemic Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. North America Sulfonylurea Hypoglycemic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Sulfonylurea Hypoglycemic Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Sulfonylurea Hypoglycemic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Sulfonylurea Hypoglycemic Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Sulfonylurea Hypoglycemic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Sulfonylurea Hypoglycemic Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. South America Sulfonylurea Hypoglycemic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Sulfonylurea Hypoglycemic Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Sulfonylurea Hypoglycemic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • First Generation Sulfonylureas
  • Second Generation Sulfonylureas
  • Third Generation Sulfonylureas
Applications
  • Pharmacy
  • Hospital
  • Clinic
  • Others
Companies covered
  • United Laboratories
  • Takeda
  • Sanofi
  • Novo Nordisk
  • Merck
  • Eli Lilly
  • Jiangsu Hengrui Pharmaceuticals
  • Pfizer
  • Beijing Double-Crane Pharmaceutical
  • Huadong Medicine
  • GSK
  • Beijing Beilu Pharmaceutical
  • AstraZeneca
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Sulfonylurea Hypoglycemic Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Sulfonylurea Hypoglycemic Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Sulfonylurea Hypoglycemic Drugs Market Dynamics
  1. 2.1 Sulfonylurea Hypoglycemic Drugs Industry Trends
  2. 2.2 Sulfonylurea Hypoglycemic Drugs Industry Drivers
  3. 2.3 Sulfonylurea Hypoglycemic Drugs Industry Opportunities and Challenges
  4. 2.4 Sulfonylurea Hypoglycemic Drugs Industry Restraints
3 Sulfonylurea Hypoglycemic Drugs Market by Company
  1. 3.1 Global Sulfonylurea Hypoglycemic Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Sulfonylurea Hypoglycemic Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Sulfonylurea Hypoglycemic Drugs Company Ranking (2024-2026)
  4. 3.4 Global Sulfonylurea Hypoglycemic Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Sulfonylurea Hypoglycemic Drugs Company Product Type and Application
  6. 3.6 Global Sulfonylurea Hypoglycemic Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Sulfonylurea Hypoglycemic Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Sulfonylurea Hypoglycemic Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Sulfonylurea Hypoglycemic Drugs Market by Type
  1. 4.1 Sulfonylurea Hypoglycemic Drugs Type Introduction
  2. 4.1.1 First Generation Sulfonylureas
  3. 4.1.2 Second Generation Sulfonylureas
  4. 4.1.3 Third Generation Sulfonylureas
  5. 4.2 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Type
  6. 4.2.1 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Type (2021-2032)
  8. 4.2.3 Global Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type (2021-2032)
5 Sulfonylurea Hypoglycemic Drugs Market by Application
  1. 5.1 Sulfonylurea Hypoglycemic Drugs Application Introduction
  2. 5.1.1 Pharmacy
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Others
  6. 5.2 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Application
  7. 5.2.1 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Application (2021-2032)
  9. 5.2.3 Global Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application (2021-2032)
6 Sulfonylurea Hypoglycemic Drugs Regional Value Analysis
  1. 6.1 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Sulfonylurea Hypoglycemic Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Sulfonylurea Hypoglycemic Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Sulfonylurea Hypoglycemic Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Sulfonylurea Hypoglycemic Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Sulfonylurea Hypoglycemic Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Sulfonylurea Hypoglycemic Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Sulfonylurea Hypoglycemic Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Sulfonylurea Hypoglycemic Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Sulfonylurea Hypoglycemic Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Sulfonylurea Hypoglycemic Drugs Sales Value Share by Country, 2025 VS 2032
7 Sulfonylurea Hypoglycemic Drugs Country-level Value Analysis
  1. 7.1 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Sulfonylurea Hypoglycemic Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Sulfonylurea Hypoglycemic Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Sulfonylurea Hypoglycemic Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Sulfonylurea Hypoglycemic Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 United Laboratories
  2. 8.1.1 United Laboratories Company Information
  3. 8.1.2 United Laboratories Business Overview
  4. 8.1.3 United Laboratories Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 United Laboratories Sulfonylurea Hypoglycemic Drugs Product Portfolio
  6. 8.1.5 United Laboratories Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Sulfonylurea Hypoglycemic Drugs Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Sulfonylurea Hypoglycemic Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Novo Nordisk
  20. 8.4.1 Novo Nordisk Company Information
  21. 8.4.2 Novo Nordisk Business Overview
  22. 8.4.3 Novo Nordisk Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novo Nordisk Sulfonylurea Hypoglycemic Drugs Product Portfolio
  24. 8.4.5 Novo Nordisk Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Sulfonylurea Hypoglycemic Drugs Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly Sulfonylurea Hypoglycemic Drugs Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Jiangsu Hengrui Pharmaceuticals
  38. 8.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
  39. 8.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  40. 8.7.3 Jiangsu Hengrui Pharmaceuticals Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jiangsu Hengrui Pharmaceuticals Sulfonylurea Hypoglycemic Drugs Product Portfolio
  42. 8.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Sulfonylurea Hypoglycemic Drugs Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Beijing Double-Crane Pharmaceutical
  50. 8.9.1 Beijing Double-Crane Pharmaceutical Company Information
  51. 8.9.2 Beijing Double-Crane Pharmaceutical Business Overview
  52. 8.9.3 Beijing Double-Crane Pharmaceutical Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Beijing Double-Crane Pharmaceutical Sulfonylurea Hypoglycemic Drugs Product Portfolio
  54. 8.9.5 Beijing Double-Crane Pharmaceutical Recent Developments
  55. 8.10 Huadong Medicine
  56. 8.10.1 Huadong Medicine Company Information
  57. 8.10.2 Huadong Medicine Business Overview
  58. 8.10.3 Huadong Medicine Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Huadong Medicine Sulfonylurea Hypoglycemic Drugs Product Portfolio
  60. 8.10.5 Huadong Medicine Recent Developments
  61. 8.11 GSK
  62. 8.11.1 GSK Company Information
  63. 8.11.2 GSK Business Overview
  64. 8.11.3 GSK Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GSK Sulfonylurea Hypoglycemic Drugs Product Portfolio
  66. 8.11.5 GSK Recent Developments
  67. 8.12 Beijing Beilu Pharmaceutical
  68. 8.12.1 Beijing Beilu Pharmaceutical Company Information
  69. 8.12.2 Beijing Beilu Pharmaceutical Business Overview
  70. 8.12.3 Beijing Beilu Pharmaceutical Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Beijing Beilu Pharmaceutical Sulfonylurea Hypoglycemic Drugs Product Portfolio
  72. 8.12.5 Beijing Beilu Pharmaceutical Recent Developments
  73. 8.13 AstraZeneca
  74. 8.13.1 AstraZeneca Company Information
  75. 8.13.2 AstraZeneca Business Overview
  76. 8.13.3 AstraZeneca Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Sulfonylurea Hypoglycemic Drugs Product Portfolio
  78. 8.13.5 AstraZeneca Recent Developments
  79. 8.14 Boehringer Ingelheim
  80. 8.14.1 Boehringer Ingelheim Company Information
  81. 8.14.2 Boehringer Ingelheim Business Overview
  82. 8.14.3 Boehringer Ingelheim Sulfonylurea Hypoglycemic Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Boehringer Ingelheim Sulfonylurea Hypoglycemic Drugs Product Portfolio
  84. 8.14.5 Boehringer Ingelheim Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst